Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
THE HEALTH SERVICE is having to move quickly to change its vaccine roll-out plans after new guidance on the use of the ‘game-changer’ AstraZeneca vaccine in older people.
The vaccination programme began with people aged over 65 living in long-term residential care facilities and frontline healthcare workers. The third phase of the programme, focusing on those aged over 70, is due to begin in the middle of this month, starting with people aged 85 and older.
It was expected that the AstraZeneca vaccine, which is easier to transport and store, would be the main vaccine used in this third phase of the programme. However advice from the National Immunisation Advisory Committee (NIAC) this week that it should only be used in those aged under 70 means some significant adjustments to the plan are required.
As part of TheJournal.ie‘s Q&A series, we have been breaking down the latest developments with vaccines and their roll-out in Ireland, trying to answer as many of your questions as we can. With these new revelations, readers have a lot of questions about what they mean for the roll-out in general and how it may affect them.
Here are some of the issues on readers’ minds this week – and what we know about them right now.
Concerns about the AstraZeneca vaccine
There has been a lot of discussion in recent days about the use of the AstraZeneca vaccine, with a number of European countries opting to restrict use of this jab to those aged under 65.
Several questions from readers were about what Irish authorities will do and whether they can choose which vaccine they get.
I am very wary about the issue of over 55s’ protection from the AstraZeneca vaccine. I am 64 and my husband is 66. Will we be given a choice of which vaccine we get? I would have more faith in the Pfizer vaccine for our age group?
Can you find out for me if I will be allowed to have a choice of vaccine when my turn comes about. I am 66. And would prefer to have either the Pfizer or Moderna vaccine because of its 90% efficacy. Can I refuse Oxford AstraZeneca one but request one of the others?
The European Medicines Agency (EMA) has stated that the AstraZeneca vaccine is safe to use in adults of all ages and protection from serious illness is “expected” in all age groups. However, it did note that there is not enough data to provide a figure for how well it works in those aged over 55. Most of the participants in the vaccine studies presented to the EMA were between 18 and 55 years old.
Further data from the vaccine developers, including results on efficacy in older people, is expected in the coming weeks. Despite the EMA’s guidance that the vaccine could be used for all adults, several European countries have decided to wait until the additional data is available and reviewed.
On Wednesday, Ireland’s immunisation advisory committee (NIAC) recommended that people aged 70 and over should receive the mRNA vaccines from Pfizer/BioNTech or Moderna “where practicable and timely”.
It recommended that for people aged 65 and older, a two-dose schedule of the Oxford/AstraZeneca vaccine at an interval of 4-6 weeks between doses is best. For those aged under 65, a two-dose schedule of the vaccine administered with 4-12 weeks between doses is recommended.
It said these recommendations are “based on current data and subject to ongoing review”.
The HSE has said – and reiterated this week – that people cannot choose which vaccine they receive. The vaccination programme is based on informed consent, so if someone does not want to be vaccinated at all, they can make that choice.
However officials have said they are conscious of people’s concerns, particularly around the absence of efficacy data for the AstraZeneca vaccine in people aged over 55.
Further data is still bring provided by vaccine developers as it becomes available. Just this week a new AstraZeneca study was published which showed that a single dose of the vaccine may reduce transmission of the coronavirus by two-thirds. The data has also shown the vaccine may be up to 82% effective if the second dose is administered 12 weeks later.
Health officials are expecting data from AstraZeneca on efficacy in older people to become available in the next couple of weeks. This will determine whether the National Immunisation Advisory Committee (NIAC) changes its advice in relation to the use of this vaccine.
It is likely that there will be a clearer picture of its efficacy by the time the programme reaches those aged 65-69 as they are in the fifth priority group, after healthcare workers who are not in direct patient contact.
Priority groups
Will other groups on the list be moved up now that the AstraZeneca vaccine won’t be used for older people? Wondering if people in high risk groups will be able to get it earlier now.
Back in December the government published its Covid-19 Vaccination Strategy and Implementation Plan.
This plan included a sequencing list, laying out the order for the various groups in society. Here is the list in full:
Adults aged 65+ years who are residents of long-term care facilities.
Frontline healthcare workers in direct patient contact roles (including vaccinators) or who risk exposure to bodily fluids or aerosols.
Aged 70 and older in the following order: 85 and older; 80-84; 75-79; 70-74.
Other healthcare workers not in direct patient contact.
Aged 65-69, prioritising those with medical conditions which put them at high risk of severe disease.
Key workers (to be further refined).
Aged 18-64 years with medical conditions which put them at high risk of severe disease.
Residents of long-term care facilities aged 18-64.
Aged 18-64 years living / working in crowded accommodation where self-isolation and social distancing is difficult to maintain.
Key workers in essential jobs who cannot avoid a high risk of exposure to Covid-19.
Those who are essential to education and who face disease exposure.
Aged 55-64 years.
Those in occupations important to the functioning of society, eg third level institutions, goods-producing industries etc.
Aged 18-54 years who did not have access to the vaccine in prior phases.
Children, adolescents up to 18 years and pregnant women (to be refined).
The HSE is still aiming to begin the rollout to those aged over 70 – starting with people aged 85 and over – from the middle of this month. There are around 480,000 people in Ireland over the age of 70 living in the community and Paul Reid said this week the intention is still to complete all vaccinations for this cohort by the end of March.
That timeline may change slightly, depending on supplies of the mRNA vaccines, but the HSE is working to try to secure additional deliveries from those suppliers.
Ireland is due to receive 40,000 vaccine doses per week from Pfizer and 10,000 doses per week from Moderna in the first quarter of the year.
While the order of the priority list is unlikely to change as a result of the recent guidance, it may bring forward the vaccination date for some groups. Ireland’s share of the 40 million AstraZeneca doses the EU has secured for the first quarter of the year is around 400,000.
Reid said recent developments may bring the AstraZeneca vaccine “into play earlier than we might have thought for other cohorts”.
“We will be immediately working towards the prioritisation that we have agreed and the sequencing we’ve agreed with government, so we’ll continue with the frontline healthcare workers – the rest of the healthcare workers, – and we’ll commence that from next week with the AstraZeneca vaccine,” he said.
He said as that supply continues to come into the country it will potentially allow for other cohorts to receive their vaccination “in parallel” with the over 70s.
GP involvement
How do GPs select people for vaccines? How will they contact people to arrange their appointments?
I’m wondering where the over 70s will go to get our vaccines. Will it be in my GPs surgery or will I have to travel to a vaccination centre?
What if someone doesn’t have a GP?
The first group in the next cohort to be vaccinated is people aged over 85 living in the community (as opposed to those living in residential care facilities).
The HSE has said they do not need to register in advance, their GPs will let them know when it is time and will arrange an appointment for them.
Advertisement
If you're aged 85 or over, you'll be offered a free #CovidVaccine next. You don't need to register in advance. As soon as your vaccine is available, your GP will let you know. For factual, expert information you can trust, visit: https://t.co/t56sdGDVdy#HoldFirmpic.twitter.com/mcCWNTGUCP
For those who do not have a GP, the HSE told TheJournal.ie that it can support them through its phone lines: 1850 241 850 or 01 240 8787.
The HSE said GPs will go through their databases and will contact patients directly to arrange their appointments with them.
And GPs have said they are already working through their records now to ensure they have up-to-date contact details for those who are due to be vaccinated next.
The developments around the AstraZeneca vaccine will not change that. Health officials still believe the best way to manage this phase of the roll-out is through GPs, who already have a relationship with and contact details for people in this cohort.
An agreement reached between the HSE and the Irish Medical Organisation on Friday night will mean that the majority of people in this age group will receive a vaccine in their own GP surgery.
For GP practices with under 200 people over the age of 70 there will be a GP-run vaccination clinic at an agreed location. The could take the form of hubs in larger urban centres. The first of these will be located at DCU in Dublin.
The use of larger vaccination centres or hubs is due to the more sensitive nature of the mRNA vaccines. They require ultra-cold temperatures at the point of storage and there is a shorter window (just five days) to use them once they are brought out of this storage for transportation.
Stephen Delaney, CEO of Q1 Scientific, a Waterford-based company that specialises in stability storage for the pharmaceutical industry, told TheJournal.ie that there are “a lot more headaches involved” when working with the Pfizer/BioNTech and Moderna vaccines in terms of transportation and storage.
“With the AstraZeneca vaccine, it has a 2-8 degree storage ability,” he said. “Working with a product like that, you can load a large truck unit, with lots of those freely available, and you could go to five depots, dropping a pellet in each location and each of those locations would have a large 2-8 degree storage.
“You have 25-30 days to get that used, so it can be transported from each of those larger locations to smaller ones like a GP surgery.
With the mRNA vaccines, with lots of little locations all over the country the samples are harder to get there and harder to store. You have a smaller window at that 2-8 degree temperature of just five days.
“And you could lose half a day transporting it across the country, doing multiple drop-offs. This is all possible, it can be done, it just puts a bit more pressure on and it means it has to be very well planned so it’s not wasted.”
Currently, when batches of the mRNA vaccines arrive, they are immediately stored in ultra-cold fridges, like these ones at Citywest:
We're preparing for the #COVID19 vaccine roll out in Ireland. At the HSE National Cold Chain Centre, we have received and are currently commissioning & validating a consignment of 9 x Ultra Low Temperature Freezers for storage of the vaccines at -75 degrees. @HSELivepic.twitter.com/ooGUc9OSQo
From here, they are transported in vehicles that can maintain a temperature of 2-8 degrees and on delivery they are moved into a fridge with the same temperature range.
Smaller deliveries to individual GP offices are, in theory, possible, according to Delaney, but he said the approach the HSE plans to take, bringing together multiple GPs in one place, would be the most practical and cost-efficient way of doing it.
“None of this is impossible, but wherever you’re adding more moving parts, you’re adding more opportunities for risk, for breakdowns in the system, and generally more operational headaches, so you want to streamline is as much as you can.
“That’s why they’ll be keen on large vaccination centres, large trucks that do a run every day and then scheduling it well so you know how many is needed. Bringing together multiple GPs reduces the likelihood that there’ll be waste if people don’y turn up for their appointment.”
Delaney pointed out that one issue the HSE will have to work out is how to get older people, who are not generally well or who are not mobile, to more larger and more centralised hubs that may be significantly further away from them than their local GP surgery.
“There are nearly 500,000 people in that over 70 group, and say 100,000 of those could be perfectly fit and healthy and can drive themselves to a location that’s further away at any time. But on the other end of the scale you could have just as many people who need assistance and can’t get there themselves.”
Dr Colm Henry, HSE Chief Clinical Officer, acknowledged this week that it will be “difficult” to organise vaccinations for people who are generally unable to leave their homes due to age or illness.
He said, however, that if it is deemed to be in their best interests to get the vaccine, arrangements can be made to bring them to a location where they can receive one.
The final details of this phase of the roll-out are now being nailed down with GPs and further details are expected to be confirmed next week.
However GPs are confident they will be able to do it.
Speaking to TheJournal.ie, Dr Denis McCauley, Donegal GP and head of the Irish Medical Organisation’s GP committee, said: “Nursing homes gave it [out], and we are equally competent, clinical people.” He said supply will be the main issue, unless the HSE can secure larger deliveries from the developers of the mRNA vaccines.
This is something that Monaghan-based GP Dr Illona Duffy is also concerned about.
“Organising for receipt of these vaccines takes a lot of work. We’ll have to be very organised with who you’re giving them to and when you’re giving them.”
Do you have a question about a particular vaccine or about the roll-out in Ireland? Send it to answers@thejournal.ie and we’ll do our best to include as many as we can in our coverage over the coming weeks.
- With reporting by Sean Murray.
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
Zelenskyy tells Fox News relationship with Trump can still be salvaged
Updated
4 hrs ago
29.5k
Baltoney
Two young men die, two others seriously injured in single-vehicle crash in Donegal
3 hrs ago
24.9k
Oval Office
Zelenskyy leaves White House summit after Trump claims he's 'not ready for peace'
Updated
13 hrs ago
95.9k
589
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 153 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 105 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 137 partners can use this purpose
Use limited data to select advertising 106 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 79 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 78 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 38 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 34 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 127 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 60 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 75 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 82 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 39 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 43 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 25 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 87 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 97 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 69 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 51 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 85 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 65 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say